前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂在实体器官移植受者中的应用。
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients.
作者信息
Warden Bruce A, Kaufman Tina, Minnier Jessica, Duell P Barton, Fazio Sergio, Shapiro Michael D
机构信息
Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon.
Oregon Health and Science University, Portland State University School of Public Health, Oregon Health and Science University, Portland, Oregon.
出版信息
JACC Case Rep. 2020 Feb 12;2(3):396-399. doi: 10.1016/j.jaccas.2019.09.026. eCollection 2020 Mar.
Abstract
Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with potential promise in this population. We describe PCSK9i as an efficacious and safe option for management of hypercholesterolemia in solid organ transplantations. ().
摘要
实体器官移植中的标准降脂疗法因与免疫抑制剂相互作用而带来挑战。前蛋白转化酶枯草溶菌素/克新9型抑制剂（PCSK9i）代表了一类新型降脂疗法，在这一人群中具有潜在前景。我们将PCSK9i描述为实体器官移植中高胆固醇血症管理的一种有效且安全的选择。（）
相似文献
1
Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients.
JACC Case Rep. 2020 Feb 12;2(3):396-399. doi: 10.1016/j.jaccas.2019.09.026. eCollection 2020 Mar.
2
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
3
Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
J Cardiovasc Pharmacol Ther. 2021 Jan;26(1):51-58. doi: 10.1177/1074248420943079. Epub 2020 Jul 30.
4
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484231186855. doi: 10.1177/10742484231186855.
5
Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
Curr Med Res Opin. 2019 May;35(5):829-835. doi: 10.1080/03007995.2018.1532885. Epub 2018 Nov 20.
6
An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Cardiovasc Ther. 2014 Apr;32(2):82-8. doi: 10.1111/1755-5922.12056.
7
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
Med Sci Monit. 2021 May 7;27:e928784. doi: 10.12659/MSM.928784.
8
The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Curr Pharm Des. 2017;23(10):1495-1499. doi: 10.2174/1381612823666170201161631.
9
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
J Clin Lipidol. 2017 May-Jun;11(3):667-673. doi: 10.1016/j.jacl.2017.03.001. Epub 2017 Mar 9.
10
Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.
Ther Clin Risk Manag. 2019 Nov 13;15:1325-1332. doi: 10.2147/TCRM.S216606. eCollection 2019.
引用本文的文献
1
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults.
Curr Atheroscler Rep. 2025 May 1;27(1):54. doi: 10.1007/s11883-025-01298-8.
2
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions.
Drugs. 2025 Mar 19. doi: 10.1007/s40265-025-02158-0.
3
Use of Evolocumab in Familial Hyperlipidemia With Isolated Heart Transplant.
JACC Case Rep. 2024 Aug 7;29(15):102426. doi: 10.1016/j.jaccas.2024.102426.
4
PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
Rev Cardiovasc Med. 2022 Nov 9;23(11):380. doi: 10.31083/j.rcm2311380. eCollection 2022 Nov.
5
Metabolic Disorders in Liver Transplant Recipients: The State of the Art.
J Clin Med. 2024 Feb 9;13(4):1014. doi: 10.3390/jcm13041014.
6
PCSK9 inhibitors in a renal transplant patient complicated with hepatitis B: A case report and literature review.
Front Cardiovasc Med. 2022 Nov 7;9:937474. doi: 10.3389/fcvm.2022.937474. eCollection 2022.
7
Dyslipidemia in Transplant Patients: Which Therapy?
J Clin Med. 2022 Jul 14;11(14):4080. doi: 10.3390/jcm11144080.
8
Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells.
Front Immunol. 2022 May 26;13:894789. doi: 10.3389/fimmu.2022.894789. eCollection 2022.
9
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients.
J Clin Med. 2022 Jun 6;11(11):3247. doi: 10.3390/jcm11113247.
本文引用的文献
1
Management of dyslipidemia in adult solid organ transplant recipients.
J Clin Lipidol. 2019 Mar-Apr;13(2):231-245. doi: 10.1016/j.jacl.2019.01.011. Epub 2019 Jan 30.
2
Pneumonia in a patient with kidney transplant treated with alirocumab and everolimus.
Farm Hosp. 2019 Mar 1;43(2):74-76. doi: 10.7399/fh.11138.
3
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.
PLoS One. 2019 Jan 16;14(1):e0210373. doi: 10.1371/journal.pone.0210373. eCollection 2019.
4
Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation.
Can J Cardiol. 2019 Jan;35(1):104.e1-104.e3. doi: 10.1016/j.cjca.2018.11.004. Epub 2018 Nov 14.
5
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
6
Safety and Efficacy of PCSK9 Inhibitor Treatment in Heart Transplant Patients.
Transplantation. 2019 Mar;103(3):e58. doi: 10.1097/TP.0000000000002520.
7
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.
Ann Intern Med. 2018 Mar 6;168(5):376-379. doi: 10.7326/M17-2485. Epub 2017 Nov 28.
8
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
9
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.
J Heart Lung Transplant. 2010 Aug;29(8):914-56. doi: 10.1016/j.healun.2010.05.034.
Zotero 插件